Steve Miller - 29 Dec 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Op. & Scientific Officer
Signature
/s/ Steve Miller
Issuer symbol
CPRX
Transactions as of
29 Dec 2025
Net transactions value
$0
Form type
4
Filing time
30 Dec 2025, 17:00:21 UTC
Previous filing
10 Dec 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Steve Miller filed Form 4 for CATALYST PHARMACEUTICALS, INC. (CPRX) on 30 Dec 2025."

Quick Takeaways

  • This page summarizes Steve Miller's Form 4 filing for CATALYST PHARMACEUTICALS, INC. (CPRX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 30 Dec 2025, 17:00.

What Changed

  • Previous filing in this sequence was filed on 10 Dec 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Miller Steve Chief Op. & Scientific Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Steve Miller 30 Dec 2025 0001402535

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise +14,000 +1.3% 1,093,803 29 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -14,000 -0.94% $0.000000 1,471,649 29 Dec 2025 Common Stock 14,000 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Derivative securities vested in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025.
F3 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 29, 2025.

Sponsored